Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clozapine, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; purified talc; colloidal anhydrous silica; magnesium stearate

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; purified talc; colloidal anhydrous silica; magnesium stearate

Canada - English - Health Canada

pharmascience inc - clozapine - tablet - 25mg - clozapine 25mg - atypical antipsychotics

Canada - English - Health Canada

pharmascience inc - clozapine - tablet - 100mg - clozapine 100mg - atypical antipsychotics

Canada - English - Health Canada

sandoz canada incorporated - clozapine - tablet - 25mg - clozapine 25mg - atypical antipsychotics

Canada - English - Health Canada

sandoz canada incorporated - clozapine - tablet - 100mg - clozapine 100mg - atypical antipsychotics

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; maize starch; purified talc; magnesium stearate; povidone - clozapine mylan is indicated in treatment-resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; colloidal anhydrous silica; povidone; magnesium stearate; purified talc - clozapine mylan is indicated in treatment-resistant schizophrenic patients only, ie. schizophrenic patients who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).